Brigatinib Dose Rationale in Anaplastic Lymphoma Kinase–Positive Non‐Small Cell Lung Cancer: Exposure–Response Analyses of Pivotal ALTA Study

Brigatinib is a kinase inhibitor indicated for patients with advanced anaplastic lymphoma kinase–positive non‐small cell lung cancer who progressed on or are intolerant to crizotinib. Approval was based on results from a randomized, dose‐ranging phase II study (ALK in Lung Cancer Trial of AP26113 (A...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Neeraj, Wang, Xiaohui, Offman, Elliot, Rich, Benjamin, Kerstein, David, Hanley, Michael, Diderichsen, Paul M., Zhang, Pingkuan, Venkatakrishnan, Karthik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762810/
https://www.ncbi.nlm.nih.gov/pubmed/33185028
http://dx.doi.org/10.1002/psp4.12569

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762810/
https://www.ncbi.nlm.nih.gov/pubmed/33185028
http://dx.doi.org/10.1002/psp4.12569

Ejemplares similares